Butylated Hydroxytoluene vs Advantame: which is worse?

What is Butylated Hydroxytoluene?

Butylated hydroxytoluene (BHT) is a synthetic lipophilic phenolic antioxidant preservative derived from petroleum. It is a white crystalline solid with chemical formula C15H24O. Like BHA, it prevents fat oxidation and is widely used in food, cosmetics, pharmaceuticals, jet fuel, and rubber.

What is Advantame?

Advantame is the newest FDA-approved synthetic sweetener, approved in 2014. Like neotame, it is a structural derivative of aspartame but with a vanillin-derived substituent. It is approximately 20,000 times sweeter than sucrose — the most potent sweetener currently approved for food use in the US.

Documented risks

Butylated Hydroxytoluene: BHT's carcinogenicity profile is complex and bidirectional. Some NTP bioassays found liver tumors in female mice at high doses, while other studies suggested BHT might inhibit tumor initiation in certain contexts. A 1986 NTP bioassay found liver tumors in female mice but anti-carcinogenic effects in the rat forestomach — making BHT's net carcinogenicity uncertain. IARC has not formally classified BHT in a specific Group due to this conflicting evidence. The NTP notes that BHT's carcinogenicity data are complex. The 'Report on Carcinogens' does not currently list BHT, unlike BHA, but the NTP has noted inconclusive evidence. Potential endocrine disruption: a 2017 study in Environmental Science & Technology found BHT disrupted thyroid hormone levels in female rats. Multiple animal studies have demonstrated weak estrogenic effects. The American Academy of Pediatrics' 2018 policy statement on food additives mentioned BHT as a synthetic preservative warranting reduced childhood exposure. Kellogg's Frosted Flakes in the US contains BHT to preserve freshness; the European version uses mixed tocopherols (vitamin E) instead — a commercially meaningful difference demonstrating feasibility of substitution. Japan banned BHT for food use based on its precautionary approach. The EU restricts it with ADI-based maximum permitted levels.

Advantame: Advantame is the newest approved high-intensity sweetener with the least post-approval safety data. The FDA approval was based on extensive pre-market animal studies showing no significant toxicity, carcinogenicity, reproductive toxicity, or neurotoxicity at relevant doses. EFSA approved it for EU use in 2014, finding no safety concerns based on the submitted data. Like other synthetic sweeteners, advantame has not been studied for long-term effects in large human populations post-approval. The same gut microbiome and glucose tolerance concerns raised for other sweeteners (aspartame, sucralose, acesulfame K) have not been specifically studied for advantame, though the class-wide concerns are relevant. Given its 2014 approval date, independent long-term safety studies are still limited.